The Institute for Clinical and Economic Review (ICER) today formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices, and explore new ways to apply evidence in a drive toward a health system that can achieve fair prices and fair access .
ICER Analytics is comprised of two tools geared toward frequent users of ICER’s work:
- The ICER Evidence Compendium™ is a rapidly searchable and sortable summary of results from ICER’s library of evidence reports.
- The ICER Interactive Modeler™ provides access to a growing set of ICER economic models, all of which will be customizable by the end user.
Insurers, health systems, and pharmacy benefit managers can use ICER Analytics in formulary development and adoption, internal assessment and P&T committee prep, long-term value and budget impact modeling, and development of outcomes-based agreements. Moreover, life sciences companies can use ICER Analytics to formulate a pre-market research or pricing strategy, inform market access strategy at launch and post-market, and catalyze the shift to a “Total Cost of Care” focus. Find out more about ICER Analytics™ here.
